Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
112 studies found for:    fatty liver | Open Studies | United States
Show Display Options
Rank Status Study
1 Recruiting Genetic Studies of Non-Alcoholic Fatty Liver Disease
Conditions: Fatty Liver;   Liver Cirrhosis;   Non-Alcoholic Fatty Liver Disease;   Liver Transplantation;   Genetics
2 Recruiting Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
Conditions: Non-alcoholic Steatohepatitis;   Fibrosis;   Liver Diseases
Interventions: Drug: Emricasan (5 mg);   Drug: Emricasan (50 mg);   Drug: Placebo
3 Recruiting Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH)
Condition: Non-Alcoholic Steatohepatitis
Interventions: Drug: SHP626;   Drug: Placebo
4 Recruiting Nonalcoholic Fatty Liver Disease (NAFLD) Adult Database 2
Condition: Liver Disease
5 Recruiting Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment
Condition: Non Alcoholic Steatohepatitis (NASH)
Interventions: Drug: Obeticholic Acid;   Drug: Placebo
6 Recruiting Combination OCA and Statins for Monitoring of Lipids (CONTROL)
Condition: Nonalcoholic Steatohepatitis
Interventions: Drug: Obeticholic Acid;   Drug: Atorvastatin;   Drug: Placebo
7 Recruiting A 5-year Longitudinal Observational Study of Patients With Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH)
Conditions: Nonalcoholic Fatty Liver Disease;   Nonalcoholic Steatohepatitis
8 Recruiting NAFLD Pediatric Database 2
Condition: Liver Disease
9 Recruiting The Effect of Acetaminophen on Non-alcoholic Fatty Liver Disease Patients
Condition: Non-alcoholic Fatty Liver Disease (NAFLD)
Intervention: Drug: Acetaminophen
10 Recruiting The Effect Of NS-0200 Versus Placebo On Hepatic Fat Content In Patients With Non Alcoholic Fatty Liver Disease
Condition: NAFLD
Interventions: Drug: Sildenafil 0.5;   Drug: Sildenafil 1.0;   Drug: Metformin;   Drug: Leucine;   Drug: Placebo
11 Recruiting A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASH
Condition: Fatty Liver
Intervention: Drug: Aramchol
12 Recruiting JKB-121 for the Treatment of Nonalcoholic Steatohepatitis
Condition: Nonalcoholic Steatohepatitis
Interventions: Drug: JKB-121: 5 mg twice daily;   Drug: JKB-121: 10 mg twice daily;   Drug: Placebo
13 Recruiting Open-Label Study To Evaluate Efficacy, Safety, Tolerability & PK of MN-001 on HDL & Triglyceride in NASH & NAFLD Subjects
Conditions: Non-alcoholic Steatohepatitis;   Hypertriglyceridemia;   Non-alcoholic Fatty Liver Disease
Intervention: Drug: MN-001
14 Recruiting Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)
Condition: Non-alcoholic Steatohepatitis
Interventions: Drug: MGL-3196;   Drug: Placebo
15 Recruiting GS-0976 in Adults With Nonalcoholic Steatohepatitis
Condition: Nonalcoholic Steatohepatitis (NASH)
Interventions: Drug: GS-0976;   Drug: Placebo
16 Recruiting A Phase ll Study of IMM-124E for Patients With Non-alcoholic Steatohepatitis
Condition: Non-alcoholic Steatohepatitis (NASH)
Interventions: Biological: IMM-124E;   Other: Placebo
17 Recruiting BREATHID Octanoate Breath Test With or Without Methacetin Breath Test for Correlation With Biopsy in NASH
Condition: Non-Alcoholic Steatohepatitis
Interventions: Device: Suspected NASH BreathID test with 13C-Octanoate;   Device: Suspected NASH Breath test with 13C Methacetin
18 Recruiting Tesamorelin Effects on Liver Fat and Histology in HIV
Conditions: Human Immunodeficiency Virus (HIV);   Nonalcoholic Fatty Liver Disease (NAFLD);   Nonalcoholic Steatohepatitis (NASH)
Interventions: Drug: tesamorelin;   Drug: Placebo
19 Recruiting A Phase II Study of the Effect of a Low Calorie Diet on Patients Undergoing Liver Resection
Conditions: Nonalcoholic Fatty Liver Disease;   Hepatic Steatosis;   Steatohepatitis
Intervention: Dietary Supplement: Optifast 800
20 Recruiting A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC 0602K in Patients With NASH
Condition: Non-alcoholic Fatty Liver Disease
Interventions: Drug: MSDC-0602K;   Drug: Placebo capsules

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years